Le Lézard
Classified in: Health
Subjects: AVO, MAT

Statement of Robin Koval, CEO and President, Truth Initiative® on the House Committee on Oversight and Reform's Subcommittee on Economic and Consumer Policy hearing, 'Examining JUUL's role in the youth e-cigarette epidemic'

WASHINGTON, July 26, 2019 /PRNewswire/ -- Congressional hearings about JUUL's role in the youth e-cigarette epidemic proved, with the company's own testimony and documents, that JUUL has become Big Tobacco 2.0. Committee members shared multiple exhibits that exposed how JUUL's strategies and actions are straight from the tobacco industry's playbook. The startling evidence presented during the questioning of JUUL Co-founder and Chief Product Officer, James Monsees, and Chief Administrative Officer Ashley Gould, indicates that:

Truth Initiative. (PRNewsFoto/Truth Initiative) (PRNewsfoto/Truth Initiative)

Despite JUUL repeatedly claiming that it is not Big Tobacco, the company's actions and testimony tell a very different story. Through repeated misrepresentations, misremembrances and obfuscation, JUUL showed itself to have studied the tone and tactics of the industry they claim to be trying to disrupt and to be taking them to a new level in what we can only characterize as Big Tobacco 2.0. The testimonies provided an abundance of new information and facts that we will share with young people through our truth® campaign to reveal how JUUL is targeting and recruiting a new generation and putting their future health at risk for profit. 


SOURCE Truth Initiative

These press releases may also interest you

at 02:05
POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the appointment of...

at 01:15
Ferring Pharmaceuticals today announced that Propess® (dinoprostone) has been approved by the Minister of Health, Labour and Welfare (MHLW) in Japan for initiation of cervical ripening in patients at term (from 37 completed weeks of gestation).1 This...

at 01:05
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive topline results from the pivotal Part 2 of the FIREFISH study, evaluating risdiplam in infants aged 1-7 months with Type 1 spinal muscular atrophy (SMA)....

at 01:00
Co-organizers Hemp & CBD China (HCC) and Asia-Pacific CBD Union (ACU) will be presenting the 520 Asia Industrial Hemp Summit & Exhibition as well as the 1st Hemp Carnival in May 2020. The 520 Asia Industrial Hemp Summit & Exhibition is a...

at 01:00
Elypta, the Swedish molecular diagnostics firm pioneering metabolism-based liquid biopsies, has raised ?6.1 million in a late seed funding round closing in December 2019 and led by Industrifonden and Sciety. Norrsken Foundation's newly raised impact...

at 01:00
SOUTH PLAINFIELD, N.J., Jan. 23, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. today announced positive topline results from part 2 of FIREFISH demonstrating that the study met its primary endpoint of proportion of infants who are sitting without...

News published on 26 july 2019 at 10:24 and distributed by: